These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30289534)

  • 1. Randomized controlled trials and real-world data: differences and similarities to untangle literature data.
    Monti S; Grosso V; Todoerti M; Caporali R
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii54-vii58. PubMed ID: 30289534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries.
    Kilcher G; Hummel N; Didden EM; Egger M; Reichenbach S;
    Rheumatology (Oxford); 2018 Feb; 57(2):354-369. PubMed ID: 29149289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.
    Vashisht P; Sayles H; Cannella AC; Mikuls TR; Michaud K
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1478-88. PubMed ID: 26866293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice.
    Aaltonen KJ; Ylikylä S; Tuulikki Joensuu J; Isomäki P; Pirilä L; Kauppi M; Rannio T; Eklund K; Blom M; Nordström D
    Rheumatology (Oxford); 2017 May; 56(5):725-735. PubMed ID: 28064209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
    Nasir A; Greenberg JD
    Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can observational studies replace or complement experiment?
    van der Linden S; Goldsmith CH; Woodcock J; Nassonova V
    J Rheumatol Suppl; 1994 Sep; 41():57-61. PubMed ID: 7799388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
    Pincus T; Sokka T
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii32-ii39. PubMed ID: 15479869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of head-to-head study designs in rheumatoid arthritis.
    R F; R L; J S S
    Semin Arthritis Rheum; 2016 Dec; 46(3):279-285. PubMed ID: 27692967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACR 20: clinical or statistical significance?
    Pincus T; Stein CM
    Arthritis Rheum; 1999 Aug; 42(8):1572-6. PubMed ID: 10446853
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized controlled trials of rheumatoid arthritis registered at ClinicalTrials.gov: what gets published and when.
    Khan NA; Singh M; Spencer HJ; Torralba KD
    Arthritis Rheumatol; 2014 Oct; 66(10):2664-74. PubMed ID: 25154608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 Feb; 37(2):323-330. PubMed ID: 28967035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies.
    Pincus T; Stein CM
    Clin Exp Rheumatol; 1997; 15 Suppl 17():S27-38. PubMed ID: 9266130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness.
    Wolfe F; Michaud K
    Rheumatology (Oxford); 2005 Dec; 44 Suppl 4():iv18-iv22. PubMed ID: 16306476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept.
    van Luijn JC; Danz M; Bijlsma JW; Gribnau FW; Leufkens HG
    Scand J Rheumatol; 2011 May; 40(3):183-91. PubMed ID: 20858147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
    Michaud K; Berglind N; Franzén S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Nyberg F; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Askling J
    Ann Rheum Dis; 2016 Oct; 75(10):1797-805. PubMed ID: 26857699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ; Wells G; Verhoeven AC; Felson DT
    Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.